WHO Raises Concern Over Severe Shortage of Obesity Medications
Less than a tenth of people eligible to benefit from GLP-1 drugs such as Wegovy can access them, warns the global health agency as it issues its initial guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging broader and more equitable availability to GLP-1 medication.
According to forecasts, more than two billion will be living with obesity by 2030 without intervention.
"The new guidelines recognises that obesity is a long-term condition that can be treated with comprehensive and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key hurdles to broad availability to the jabs that can help people shift considerable body mass, notes the organization.
Skinny Jab Supply Crisis
Even in the current best projected outlook, the supply of GLP-1 therapies would only suffice for around 100 million people – less than 10% of those who need them, per the health organization.
The recommendation encourages nations and manufacturers to widen availability, via measures like voluntary licensing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026.
How Obesity Injections Function
The injections imitate a natural hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so users eat less.
People usually start to lose weight within a few weeks of starting on the regular doses.
Evidence suggests patients may put most of the weight back on a year later of discontinuing the medication, because their typical hunger resume.
To be carrying excess weight raises your risk for experiencing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts people in every country and was associated with millions of fatalities worldwide in 2024, as per the WHO.
